Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 36-41

  Alexandre, J ^a   Gross Goupil, M ^b   Falissard, B ^c   Nguyen, M L ^a   Gornet, J M ^b   Misset, J L ^b   Goldwasser, François ^a  

^a Groupe Hospitalier Cochin ^*  (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Albumin; C reative protein; Chemotherapy; Performance status; Topotecan

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BILIRUBIN; C REACTIVE PROTEIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HEMOGLOBIN; IFOSFAMIDE; IRINOTECAN; NAVELBINE; OROSOMUCOID; OXALIPLATIN; PACLITAXEL; PREALBUMIN; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHI SQUARE TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; NUTRITIONAL STATUS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 12244285294     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg013     Document Type: Article

References (36)

1. Huitema AD, Mathot RA, Tibben MM et al. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001; 23: 650-657.
2. Mathijssen RH, Verweij J, de Jonge MJ et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20: 81-87.
3. Apelgren K, Rombeau JL, Twomey PL, Miller RA. Comparison of nutritional indices and outcome in critically ill patients. Crit Care Med 1982; 10: 305-307.
4. Chang RW, Jacobs S, Lee B. Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition. Lancet 1986; 1: 1483-1486.
5. Finn PJ, Plank LD, Clark MA et al. Progressive cellular dehydration and proteolysis in critically ill patients. Lancet 1996; 347: 654-656.
6. Dybowski R, Weller P, Chang R et al. Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm. Lancet 1996; 347: 1146-1150.
7. Douglas RG, Shaw JHF. Metabolic response to sepsis and trauma. Br J Surg 1989; 76: 115-122.
8. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med 1994; 325: 525-532.
9. Fan S-T, Lo C-M, Lai E et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 33: 1547-1552.
10. Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med 1981; 305: 375-382.
11. DeWys WD. Nutritional care of the cancer patient. JAMA 1980; 244: 374-376.
12. Wigmore SJ, MacMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Cancer 2001; 88: 255-260.
13. Andreyev HJN, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503-509.
14. Aslani A, Smith RC, Allen BJ et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88: 796-803.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Ingelbleeck Y, Carpentier YA. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vit Nutr Res 1985; 55: 91-101.
17. Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol 1975; 12: 387-395.
18. Kohn KW, Jackman J, O'Connor P. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440-452.
19. Zhou B-BS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
20. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-528.
21. Montazeri A, Culine S, Laguerre B et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002; 8: 394-399.
22. O'Reilly S, Rowinsky E, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-3073.
23. Alexandre J, Bleuzen P, Bonneterre J et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000; 18: 562-573.
24. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
25. De Jongh FE, Verweij J, Loos WJ. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19: 3733-3739.
26. Goldwasser F, Gross-Goupil M, Tigaud JM et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann Oncol 2000; 11: 1463-1470.
27. Roila F, Lupattelli M, Sassi M et al. Intra- and inter-observer variability in cancer patients performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 1991; 2: 437-439.
28. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998; 11: 48-51.
29. Rivory LP, Slaviero KA, Seale P et al. Prognostic inflammatory and nutritional index correlates with drug hepatic metabolism in cancer patients. Proc Am Soc Clin Oncol 2001; 20: 112a.
30. Blay JY, Chauvin F, Le Cesne A et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636-643.
31. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
32. Ray-Coquard I, Le Cesne A, Rubio MT et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999; 17: 2840-2846.
33. Blay JY, Le Cesne A, Mermet C et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92: 405-410.
34. Goldwasser F, Buthaud X, Gross M et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-Cancer Drugs 1999; 10: 263-265.
35. Arriagada R, Le Chevalier T, Pignon JP et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848-1852.
36. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14: 2113-2119.